From: scimedweb on
Recent review articles about renal cancer :

Laparoscopic partial nephrectomy in the treatment of renal cell
carcinoma: a minimally invasive means to nephron preservation.
Blitstein J, Ghavamian R.
Expert Rev Anticancer Ther. 2008 Jun;8(6):921-7.

Immunotherapy for renal cell cancer in the era of targeted therapy.
Coppin C.
Expert Rev Anticancer Ther. 2008 Jun;8(6):907-19.

Molecular genetics of hereditary renal cancer: new genes and
diagnostic and therapeutic opportunities.
Hansel DE, Rini BI.
Expert Rev Anticancer Ther. 2008 Jun;8(6):895-905.

Chemokines as therapeutic targets in renal cell carcinoma.
Reckamp KL, Strieter RM, Figlin RA.
Expert Rev Anticancer Ther. 2008 Jun;8(6):887-93.

Metastatic renal cell carcinoma: recent advances and current
therapeutic options.
Schrader AJ, Hofmann R.
Anticancer Drugs. 2008 Mar;19(3):235-45.

Factors associated with outcome in patients with advanced renal cell
carcinoma in the era of antiangiogenic agents.
Choueiri TK.
Clin Genitourin Cancer. 2008 Mar;6(1):15-20.

New anti-angiogenic targeted therapy in advanced renal cell carcinoma
(RCC): current status and future prospects.
Sciarra A, Gentile V, Salciccia S, Alfarone A, Di Silverio F.
Rev Recent Clin Trials. 2008 May;3(2):97-103.

Molecular targeting agents in renal cell carcinoma: present strategies
and future perspectives.
Bjelogrlic SK, Radulovic S, Babovic N.
Curr Pharm Des. 2008;14(11):1058-77.

Poor usage of HUGO standard gene nomenclature in cancer marker
studies.
Lacroix M.
Int J Biol Markers. 2008 April - June;23(2):123-126.

Targeted therapies in the treatment of renal cell carcinoma.
Pezaro C, Davis ID.
Curr Med Chem. 2008;15(12):1166-74.

Targeted therapy for metastatic renal cell carcinoma: a home run or a
work in progress?
Rini BI, Bukowski RM.
Oncology (Williston Park). 2008 Apr 15;22(4):388-96

Axitinib for renal cell carcinoma.
Sonpavde G, Hutson TE, Rini BI.
Expert Opin Investig Drugs. 2008 May;17(5):741-8.

Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to
systemic therapy, and future vaccine strategies.
Shuch B, Li Z, Belldegrun AS.
BJU Int. 2008 Jun;101 Suppl 4:25-30.

Diagnostic and prognostic molecular markers in renal cell carcinoma.
Tunuguntla HS, Jorda M.
J Urol. 2008 Jun;179(6):2096-102.

Management of renal cancer in the tyrosine kinase inhibitor era: a
view from 3 years on.
Samlowski WE, Wong B, Vogelzang NJ.
BJU Int. 2008 Jul;102(2):162-5.

Renal cell carcinoma.
Rini BI, Rathmell WK, Godley P.
Curr Opin Oncol. 2008 May;20(3):300-6.

Temsirolimus: in advanced renal cell carcinoma.
Simpson D, Curran MP.
Drugs. 2008;68(5):631-8.

Angiogenesis and angiogenic inhibitors in renal cell carcinoma.
Sawhney R, Kabbinavar F.
Curr Urol Rep. 2008 Jan;9(1):26-33.

Genomics and proteomics in renal cell carcinoma: diagnosis, prognosis,
and treatment selection.
Jones J, Pantuck AJ.
Curr Urol Rep. 2008 Jan;9(1):9-14.


(contact at InTextoResearch: Marc Lacroix, Baelen, Wallonia, Belgium -
scimedweb(a)mail.com)